At a glance
ClinicalIndex Comparison Record- ✓Aged 18-65 years
- ✓Meets DSM-5 criteria for opioid use disorder with physical dependence
- ✓Urine positive for fentanyl and/or fentanyl analogues
- ✓Interested in buprenorphine maintenance for OUD
- ✕Medically contraindicated for buprenorphine, XR-buprenorphine, or suvorexant
- ✕Pregnant or breast feeding
- ✕Severe DSM-5 alcohol or benzodiazepine use disorder or evidence of physical dependence
- ✕Known allergy to study medications
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl
In Brief
A Phase 2 clinical trial evaluating Suvorexant and Placebo for Suvorexant and 2 related conditions. Currently recruiting, targeting 120 participants across 1 site.
Detailed Summary
This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine/naloxone and transitioned to extended-release buprenorphine).
Study Details
Timeline
Interventions
Encapsulated suvorexant (matched for color, weight, and size)
Encapsulated placebo (matched for color, weight, and size)